Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Tan

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis and Rare CFTR Variants: In Vitro Translation to a Phase 3, Double-Blind, Randomized, Placebo-controlled Trial and Real-World StudyCarlo Castellani, Pedro Mondejar-Lopez, Fredrick Van Goor, et al.
American Journal of Respiratory and Critical Care Medicine|April 10, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Extension StudyCori L Daines, Deepika Polineni, Elizabeth Tullis, et al.
The European Respiratory Journal|November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension studyCori L Daines, Elizabeth Tullis, Stefano Costa, et al.
Nature Communications|March 30, 2016
Meta-analysis of gene-environment-wide association scans accounting for education level identifies additional loci for refractive errorQiao Fan, Virginie J M Verhoeven, Robert Wojciechowski, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis and Rare CFTR Variants: In Vitro Translation to a Phase 3, Double-Blind, Randomized, Placebo-controlled Trial and Real-World StudyCarlo Castellani, Pedro Mondejar-Lopez, Fredrick Van Goor, et al.
American Journal of Respiratory and Critical Care Medicine|April 10, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Extension StudyCori L Daines, Deepika Polineni, Elizabeth Tullis, et al.
The European Respiratory Journal|November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension studyCori L Daines, Elizabeth Tullis, Stefano Costa, et al.
Nature Communications|March 30, 2016
Meta-analysis of gene-environment-wide association scans accounting for education level identifies additional loci for refractive errorQiao Fan, Virginie J M Verhoeven, Robert Wojciechowski, et al.
Pageof 2